Announcements

Updates on campus events, policies, construction and more.

close  

Information for Our Community

Whether you are part of our community or are interested in joining us, we welcome you to Washington University School of Medicine.

close  


Visit the News Hub

Racial differences in Alzheimer’s research focus of $15 million grant

Study investigates whether biological markers of Alzheimer’s in white patients also apply to African Americans

by Julia Evangelou StraitOctober 12, 2020

Getty Images

In efforts to identify who is at risk of developing Alzheimer’s dementia, researchers over the years have zeroed in on several signs — or biological markers — that indicate early stages of the disease. If individuals could be identified long before symptoms of dementia begin to appear, doctors could target those patients with future preventive therapies.

But those early markers of disease — whether found in blood, cerebrospinal fluid or brain scans — have been identified primarily in white populations. Whether these disease markers also apply to African Americans remains an open question.

A $14.6 million grant to Washington University School of Medicine in St. Louis will support studies to investigate whether early markers of Alzheimer’s that have shown promise for predicting the disease in white populations also predict the disease in African Americans. The researchers also will seek biological and social determinants of health that may explain the possible racial differences in these markers.

“Past studies have produced conflicting data about African Americans and Alzheimer’s disease,” said Chengjie Xiong, PhD, a professor of biostatistics and interim director of the Division of Biostatistics within the Institute for Informatics. “Mainly, the problem is that the sample sizes of African Americans in any given study are too small to be able to draw definitive conclusions about the disease in African American populations. We want to understand whether Alzheimer’s is, in fact, the same disease in white and African American populations, both in the silent stage before symptoms and in the symptomatic stage.”

The researchers will combine existing data from earlier studies to obtain a larger sample size of African Americans. They also will add prospectively collected data from new studies currently underway; these include investigations of Alzheimer’s disease markers in this underrepresented population and how the markers change over time. The researchers will re-analyze existing samples and brain scans collected from past participants along with prospectively collected samples and scans, including cerebrospinal fluid, MRI scans and positron emission tomography (PET) scans. The cerebrospinal fluid samples and imaging scans can reveal the presence of protein plaques and tangles in the brain — called amyloid plaques and tau tangles — that build up silently for a long period of time and eventually interfere with cognition.

The ongoing clinical and biomarker studies that will be incorporated into this analysis include studies being conducted at the Washington University Knight Alzheimer Disease Research Center, the University of Pennsylvania Alzheimer Disease Core Center, the Emory University Alzheimer Disease Research Center, the Harvard Aging Brain Study, and the Anti-Amyloid Treatment of Asymptomatic Alzheimer’s trial.

The harmonization of clinical and cognitive data across the studies will be led by John Morris, MD, the Harvey A. & Dorismae Hacker Friedman Distinguished Professor of Neurology and director of the Knight Alzheimer Disease Research Center; and Jason Hassenstab, PhD, an associate professor of neurology and the psychometrics leader of the center. The central reprocessing of the samples and scans across the studies will be led by Anne Fagan, PhD, a professor of neurology; and Tammie Benzinger, MD, PhD, a professor of radiology, who lead the Fluid Biomarker Core and Neuroimaging Core of the Knight Alzheimer Disease Research Center. The recruitment will be led by Joyce Balls-Berry, PhD, an associate professor of neurology and the leader of the Health Disparities and Equity Core.

Altogether, the effort will include a total of over 1,000 African American participants and will produce adequate statistical power required to assess biologically significant differences that might exist between the markers of Alzheimer’s disease in white participants and those in African American populations. For example, one question the researchers would like to answer is whether the protein tau is as important in African American populations as it seems to be in white populations.

“There is some evidence, though it’s not conclusive, that middle-aged and elderly African Americans have lower levels of tau in the cerebrospinal fluid than white people of similar ages,” Xiong said. “If this is true and a treatment is developed that reduces tau levels, it’s possible it won’t work well in African Americans. Understanding the disease in African Americans is crucial and will help guide the development of effective treatments.”

This work is supported by the National Institutes of Health (NIH), grant number 1R01AG067505.

Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

Julia covers medical news in genomics, cancer, cardiology, developmental biology, otolaryngology, biochemistry & molecular biophysics, and gut microbiome research. In 2022, she won a gold award for excellence in the Robert G. Fenley Writing Awards competition. Given by the Association of American Medical Colleges, the award recognized her coverage of long COVID-19. Before joining Washington University in 2010, she was a freelance writer covering science and medicine. She has a research background with stints in labs focused on bioceramics, human motor control and tissue-engineered heart valves. She is a past Missouri Health Journalism Fellow and a current member of the National Association of Science Writers. She holds a bachelor's degree in engineering science from Iowa State University and a master's degree in biomedical engineering from the University of Minnesota.